Advertisement

x

International Precision Medicine Conference

April 19-21, 2021 | Orlando, USA

Scopus Indexed Conference
scopus
Holiday Inn Orlando SW Celebration Area, 5711 W. Irlo Bronson Memorial Highway, Kissimmee, FL 34746, USA
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 (540) 709-1879
Email: precision@magnus-event.com
April 19-21, 2021 | Orlando, USA

Huiqin Yang

Keynote Speaker for IPMC 2020
Huiqin Yang
University of Exeter Medical School, UK
Title : Evaluation of clinical effectiveness of using enzyme-linked immunosorbent assay (ELISA) tests for measuring drug levels and/or anti-drug antibodies for the purpose of monitoring treatment response and guiding decisions about the use of tumour necrosis fact

Abstract:

This research assessed the clinical effectiveness of using enzyme-linked immunosorbent assay (ELISA) tests to measure drug levels and/or their anti-drug antibodies for monitoring response to TNF-α inhibitors in rheumatoid arthritis patients who had achieved treatment target (remission or low disease activity), or experienced a primary non-response or a secondary non-response. A range of bibliographic databases including MEDLINE and EMBASE were searched from inception to November 2018. Both randomised controlled trials and non-randomised controlled studies comparing therapeutic drug monitoring by using ELISA tests with standard care were included. The eligible ELISA test kits (Promonitor, IDKmonitor, LISA-TRACKER, RIDASCREEN, MabTrack and Sanquin) for monitoring response to TNF-α inhibitors were used to measure drug levels and/or their anti-drug antibodies. The eligible populations were patients with rheumatoid arthritis who were being treated with a TNF-α inhibitor (adalimumab, etanercept, infliximab, certolizumab pegol or golimumab) and had achieved treatment target (remission or low disease activity), or experienced a primary non-response or a secondary non-response. The risk of bias was assessed using the Cochrane (ROBINS-1) tool for non-randomised studies with adaptations as appropriate. A narrative synthesis approach was employed due to considerable clinical heterogeneity between included studies. This talk will give an overview of research findings and highlight methodological challenges and its important implications for future research.
Audience Take Away:
  • Learn research topic within precision medicine
  • Improve understanding of methodological limitations and learn approaches to addressing methodological challenges
  • Improve study design

Biography:

Dr Huiqin Yang is Senior Research Fellow in Health Technology Assessment and Deputy Director of the Peninsula Technology Assessment Group (PenTAG) at the University of Exeter, UK. She has over 13 years research experience in Health Services Research and she has undertaken a range of Health Technology Assessment (HTA) projects for the National Institute for Health and Clinical Excellence (NICE) and the National Institute for Health Research (NIHR) HTA Programme within a wide range of areas. She has PhD in Medical Decision Making from the University of York and she is an Associate Editor of BMC Health Services Research.

Watsapp